Logo image of VIVE

VIVEVE MEDICAL INC (VIVE) Stock Fundamental Analysis

USA - NASDAQ:VIVE - US92852W5013 - Common Stock

0.2201 USD
-0.04 (-15.35%)
Last: 1/18/2023, 8:00:02 PM
0.2151 USD
0 (-2.27%)
After Hours: 1/18/2023, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VIVE. VIVE was compared to 188 industry peers in the Health Care Equipment & Supplies industry. The financial health of VIVE is average, but there are quite some concerns on its profitability. While showing a medium growth rate, VIVE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VIVE had negative earnings in the past year.
VIVE had a negative operating cash flow in the past year.
VIVE Yearly Net Income VS EBIT VS OCF VS FCFVIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

VIVE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VIVE Yearly ROA, ROE, ROICVIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 1K -1K 2K 3K 4K

1.3 Margins

The Gross Margin of VIVE (16.39%) is worse than 78.34% of its industry peers.
In the last couple of years the Gross Margin of VIVE has declined.
The Profit Margin and Operating Margin are not available for VIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.5%
GM growth 5Y-22.91%
VIVE Yearly Profit, Operating, Gross MarginsVIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

VIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIVE has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, VIVE has an improved debt to assets ratio.
VIVE Yearly Shares OutstandingVIVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
VIVE Yearly Total Debt VS Total AssetsVIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -34.95, we must say that VIVE is in the distress zone and has some risk of bankruptcy.
VIVE's Altman-Z score of -34.95 is on the low side compared to the rest of the industry. VIVE is outperformed by 94.47% of its industry peers.
VIVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.95
ROIC/WACCN/A
WACC8.03%
VIVE Yearly LT Debt VS Equity VS FCFVIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M -40M

2.3 Liquidity

VIVE has a Current Ratio of 0.89. This is a bad value and indicates that VIVE is not financially healthy enough and could expect problems in meeting its short term obligations.
VIVE's Current ratio of 0.89 is on the low side compared to the rest of the industry. VIVE is outperformed by 94.47% of its industry peers.
A Quick Ratio of 0.74 indicates that VIVE may have some problems paying its short term obligations.
VIVE has a worse Quick ratio (0.74) than 88.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.74
VIVE Yearly Current Assets VS Current LiabilitesVIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.74% over the past year.
Looking at the last year, VIVE shows a small growth in Revenue. The Revenue has grown by 2.34% in the last year.
The Revenue has been decreasing by -2.09% on average over the past years.
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.94%
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y-2.09%
Sales Q2Q%4.21%

3.2 Future

Based on estimates for the next years, VIVE will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.12% on average per year.
VIVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.55% yearly.
EPS Next Y7.44%
EPS Next 2Y19.13%
EPS Next 3Y18.12%
EPS Next 5YN/A
Revenue Next Year7.41%
Revenue Next 2Y31.78%
Revenue Next 3Y50.55%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VIVE Yearly Revenue VS EstimatesVIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
VIVE Yearly EPS VS EstimatesVIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIVE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIVE Price Earnings VS Forward Price EarningsVIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVE Per share dataVIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as VIVE's earnings are expected to grow with 18.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.13%
EPS Next 3Y18.12%

More info and screens

0

5. Dividend

5.1 Amount

VIVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVEVE MEDICAL INC

NASDAQ:VIVE (1/18/2023, 8:00:02 PM)

After market: 0.2151 0 (-2.27%)

0.2201

-0.04 (-15.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10 2022-11-10/amc
Earnings (Next)03-15 2023-03-15
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners2.98%
Ins Owner Change0%
Market Cap2.36M
Revenue(TTM)6.83M
Net Income(TTM)-28.14M
Analysts85
Price Target4.77 (2067.2%)
Short Float %0.04%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.16%
Min EPS beat(2)1.96%
Max EPS beat(2)12.36%
EPS beat(4)3
Avg EPS beat(4)-0.41%
Min EPS beat(4)-18.64%
Max EPS beat(4)12.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-3.16%
Max Revenue beat(2)0%
Revenue beat(4)0
Avg Revenue beat(4)-3.09%
Min Revenue beat(4)-7.29%
Max Revenue beat(4)0%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.34%
EPS NY rev (1m)0%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.64
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.5%
GM growth 5Y-22.91%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.74
Altman-Z -34.95
F-Score4
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)64.33%
Cap/Depr(5y)133.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.94%
EPS Next Y7.44%
EPS Next 2Y19.13%
EPS Next 3Y18.12%
EPS Next 5YN/A
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y-2.09%
Sales Q2Q%4.21%
Revenue Next Year7.41%
Revenue Next 2Y31.78%
Revenue Next 3Y50.55%
Revenue Next 5YN/A
EBIT growth 1Y-6.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.4%
OCF growth 3YN/A
OCF growth 5YN/A

VIVEVE MEDICAL INC / VIVE FAQ

What is the ChartMill fundamental rating of VIVEVE MEDICAL INC (VIVE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VIVE.


What is the valuation status for VIVE stock?

ChartMill assigns a valuation rating of 2 / 10 to VIVEVE MEDICAL INC (VIVE). This can be considered as Overvalued.


Can you provide the profitability details for VIVEVE MEDICAL INC?

VIVEVE MEDICAL INC (VIVE) has a profitability rating of 1 / 10.


How financially healthy is VIVEVE MEDICAL INC?

The financial health rating of VIVEVE MEDICAL INC (VIVE) is 2 / 10.